B. Riley Brokers Reduce Earnings Estimates for Perspective Therapeutics, Inc. (NYSE:CATX)

Perspective Therapeutics, Inc. (NYSE:CATX) – Analysts at B. Riley decreased their Q2 2024 EPS estimates for shares of Perspective Therapeutics in a report issued on Monday, July 1st. B. Riley analyst Y. Zhi now anticipates that the company will post earnings of ($0.21) per share for the quarter, down from their previous forecast of ($0.20). B. Riley currently has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.00) per share. B. Riley also issued estimates for Perspective Therapeutics’ Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.85) EPS and FY2025 earnings at ($1.01) EPS.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The company had revenue of $0.33 million for the quarter.

CATX has been the subject of a number of other reports. Oppenheimer restated an “outperform” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 25th. Royal Bank of Canada restated an “outperform” rating and set a $30.00 price objective on shares of Perspective Therapeutics in a research report on Friday, June 14th. Finally, Lifesci Capital restated an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $19.00.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $10.75 on Wednesday. The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a fifty-two week low of $2.05 and a fifty-two week high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. ZWJ Investment Counsel Inc. acquired a new stake in shares of Perspective Therapeutics during the first quarter valued at about $26,000. Simplicity Wealth LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter valued at about $40,000. Bleakley Financial Group LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter valued at about $40,000. RIA Advisory Group LLC increased its position in shares of Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after acquiring an additional 99,293 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter valued at about $138,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 3,003 shares of Perspective Therapeutics stock in a transaction dated Wednesday, May 29th. The stock was acquired at an average cost of $13.30 per share, for a total transaction of $39,939.90. Following the completion of the transaction, the director now directly owns 36,879 shares of the company’s stock, valued at $490,490.70. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Lori A. Woods acquired 4,587 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average cost of $10.90 per share, for a total transaction of $49,998.30. Following the completion of the transaction, the director now owns 159,985 shares in the company, valued at $1,743,836.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert F. Williamson III acquired 3,003 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The shares were purchased at an average price of $13.30 per share, with a total value of $39,939.90. Following the completion of the transaction, the director now owns 36,879 shares of the company’s stock, valued at approximately $490,490.70. The disclosure for this purchase can be found here. Insiders acquired 30,814 shares of company stock worth $385,487 over the last three months. Insiders own 3.52% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.